ClinicalTrials.gg
RecruitingNCT05647564Updated Oct 1, 2026

PET/CT Characterization of Treatment Resistance

An interventional study of F-fluorodeoxyglucose positron emission tomography (FDG PET) and prostate-specific membrane antigen positron emission tomography (PSMA PET) in Prostate Cancer, sponsored by University of Wisconsin, Madison. Recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by University of Wisconsin, Madison · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.
Updated Oct 1, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Prostatic Neoplasms by University of Wisconsin, Madison — 5 open to participants now, 10 under way, none of them phase 3. Prostatic Neoplasms · University of Wisconsin, Madison.

Planned enrollment
18th of 33
25 · median 30
Started
2023
with 1 other
No phase
4 of 38
1 open now
Registered
34th of 38
by date

Among the 38 studies in Prostatic Neoplasms by University of Wisconsin, Madison, this one is the 18th largest by planned enrollment of the 33 interventional ones that give a count, is one of 2 that started in 2023, is one of 4 with no phase, and was the 34th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

5 of the 38 studies in Prostatic Neoplasms by University of Wisconsin, Madison are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Prostatic Neoplasms by University of Wisconsin, Madison, or all of them as a file.
02

Study summary

This study will use different types of medical imaging to assess how lesions from advanced prostate cancer become resistant to second-generation AR-targeted therapy, and how the different types of imaging compare in that assessment. Participants in this study have advanced prostate cancer and are either scheduled to start a second-generation androgen receptor (AR) targeted therapy (such as enzalutamide, abiraterone, or apalutamide) or are already being treated with one. Participants can expect to be in the study for at least 9 months, and up to 2 years.

Read the detailed description

There are two groups, or cohorts, in this study. Participants are assigned to Cohort A if they have advanced prostate cancer and are scheduled to start a second-generation AR-targeted therapy (such as enzalutamide, abiraterone, darolutamide, or apalutamide) or PSMA directed radiotherapy (e.g. Lu177-PSMA radio-ligand therapy. Participants are assigned to Cohort B if they have advanced prostate cancer, are already on a second-generation AR-targeted therapy, and have shown an increase in their PSA (prostate-specific antigen) levels.

There are two medical imaging scans that will be done for research purposes in this study. One is called 18F-fluorodeoxyglucose positron emission tomography (FDG PET) and the other is prostate-specific membrane antigen positron emission tomography (PSMA PET). These scans are done simultaneously with computed tomography (CT) scanning. Participants will be scheduled to have 6 scans, 3 FDG PET/CT scans and 3 PSMA PET/CT scans.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • androgen receptor targeted therapy
  • imaging
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven adenocarcinoma of the prostate.
  • At least 1 radiographic as seen on conventional CT imaging or bone scan
  • Progressive prostate cancer as evident by at least two separate increase in PSA over nadir, and absolute PSA value at least 2 ng/ml (INTRINSIC RESISTANCE COHORT, ARSI patients ONLY)
  • Patients must be candidate for a second-generation androgen receptor (AR) inhibitor (e.g. enzalutamide, abiraterone, darolutamide, apalutamide), or Lu177-PSMA radioligand therapy (INTRINSIC RESISTANCE COHORT ONLY)
  • Men of age >18 years.
  • Patients must be able to comply with all study procedures, including having both the ability and willingness to lie flat for ≥ 30 minutes during imaging
  • Patients must be informed of the exploratory nature of the study and its potential risks, and must sign IRB-approved consent form indicating such understanding.
  • Life-expectancy at least 12 months
  • Patients currently receiving a second-generation androgen receptor (AR) inhibitor (e.g. enzalutamide, abiraterone, darolutamide, apalutamide) and must have had 1) PSA decline on treatment and 2) now have PSA increase over nadir while still on treatment (patients must be registered within 12 weeks of first documented PSA increase) (ACQUIRED RESISTANCE COHORT ONLY)

Exclusion criteria

Exclusion Criteria:

  • Must not have uncontrolled diabetes (fasting blood sugar > 200 mg/dL or inability to safely hold diabetes medication or fast 6 hours prior to FDG PET scan)
  • Prior treatment with second-generation AR inhibitor for prostate cancer in the disease setting (prior second-generation AR inhibitor in the or adjuvant setting is permitted unless patient developed progression while on treatment) (INTRINSIC RESISTANCE COHORT, AR-INHIBITOR GROUP ONLY)
  • Pain or clinical symptoms from metastatic prostate cancer requiring opioid analgesics
  • Known neuro-endocrine prostate cancer
  • Prior radioisotope therapy for castration-resistant prostate cancer
  • To avoid the possibility of unintended coercion, vulnerable populations such as incarcerated subjects, subjects unable to provide their own and non-English speaking patients will not be considered
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Other
    Intrinsic Resistance Cohort (Cohort A)

    Participants assigned to Cohort A have advanced prostate cancer and are scheduled to start a second-generation AR-targeted (such as enzalutamide, abiraterone, darolutamide, or apalutamide) or PSMA directed (e.g. Lu177-PSMA) therapies .

    Diagnostic Test: F-fluorodeoxyglucose positron emission tomography (FDG PET) · Diagnostic Test: prostate-specific membrane antigen positron emission tomography (PSMA PET)

  • Other
    Acquired Resistance Cohort (Cohort B)

    Participants are assigned to Cohort B if they have advanced prostate cancer, are already on a second-generation AR-targeted therapy, and have shown an increase in their PSA (prostate-specific antigen) levels.

    Diagnostic Test: F-fluorodeoxyglucose positron emission tomography (FDG PET) · Diagnostic Test: prostate-specific membrane antigen positron emission tomography (PSMA PET)

Interventions

  • Diagnostic testF-fluorodeoxyglucose positron emission tomography (FDG PET)

    Imaging scan

  • Diagnostic testprostate-specific membrane antigen positron emission tomography (PSMA PET)

    Imaging scan

06

What researchers measure

Primary outcomes

  1. Characterize intrinsic resistance based on FDG and PSMA PET through change in individual lesion update levels.

    Changes in individual lesion update levels (ΔiSUVtotal) will be calculated. SUVtotal is a metric of activity, for which less activity is better.

    Time frame: Baseline to 12 weeks

  2. Characterize change in intrinsic resistance based on FDG and PSMA PET.

    Changes in individual lesion update levels (ΔiSUVtotal) will be calculated. SUVtotal is a metric of activity, for which a decrease in activity is better.

    Time frame: Baseline to 12 weeks

  3. Characterize change in intrinsic resistance based on FDG and PSMA PET.

    Changes in individual lesion update levels (ΔiSUVtotal) will be calculated. SUVtotal is a metric of activity, for which a decrease in activity is better.

    Time frame: 12 weeks to 36 weeks

  4. Characterize change in intrinsic resistance based on FDG and PSMA PET.

    Changes in individual lesion update levels (ΔiSUVtotal) will be calculated. SUVtotal is a metric of activity, for which a decrease in activity is better.

    Time frame: Baseline to 36 weeks

  5. Characterize acquired resistance at the time of progression

    Percentage and absolute changes in individual lesion update levels (ΔiSUVtotal) will be calculated.

    Time frame: Baseline to 36 weeks

Secondary outcomes

  1. Correlate amount of intrinsic resistance on FDG and PSMA PET to predict time to PSA progression

    Analysis will be conducted to evaluate whether changes in lesion uptake values predict time to PSA progression. PSA progression will be 25% increase and \>2 ng/mL above PSA nadir

    Time frame: Baseline to 36 weeks

  2. Correlate amount of intrinsic resistance on FDG and PSMA PET to predict time to radiographic progression

    Analysis will be conducted to evaluate whether changes in lesion uptake values predict time to radiographic progression. Time to radiographic progression will be defined as the number of days to confirmed radiographic progression using Prostate Cancer WorkingGroup 3 (PCWG3) criteria.

    Time frame: Baseline to 36 weeks

  3. Correlate amount of intrinsic resistance on FDG and PSMA PET to predict time duration on treatment

    Analysis will be conducted to evaluate whether changes in lesion uptake values predict duration of treatment. Duration of treatment will be defined as the time from treatment start, to treatment discontinuation (and reason for discontinuation) using PCWG3 criteria.

    Time frame: Up to 36 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Dec 2027, 56 months after the start.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 56 months is above that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: primary completion Dec 2026 → Dec 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2022
First posted
Dec 12, 2022
StartActual
Mar 6, 2023
Primary completionEst.
Dec 1, 2027was Dec 2026
CompletionEst.
Dec 1, 2027was Dec 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 1, 2026→Dec 1, 2027
Oct 1, 2026
Study completion
Dec 1, 2026→Dec 1, 2027
Oct 1, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • University of Wisconsin · Madison, United StatesContact person changed (no phone or email listed)
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Primary completion Dec 1, 2026→Dec 1, 2027
    Study completion Dec 1, 2026→Dec 1, 2027
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University of Wisconsin · Madison, United StatesContact person changed (no phone or email listed)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05647564
Responsible party
Sponsor
First posted
Dec 12, 2022
Start date
Mar 6, 2023
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Oct 1, 2026

Study contacts

Cancer Connect
Contact
clinicaltrials@cancer.wisc.edu
800-622-8922
Glenn Liu, MD
principal investigator · University of Wisconsin, Madison
Robert Jeraj, PhD
principal investigator · University of Wisconsin, Madison

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion